Phase 1/2 trial of ATR inhibitor berzosertib plus immune checkpoint inhibitor avelumab in patients with advanced cancers with DNA damage response (DDR) gene alterations: Tumor microenvironment–mediated pathways of resistance from correlative data.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Patrick Glen Pilié, Nejla Ozirmak Lermi, Idania Lubo, Khaja Khan, Wei Lu, Bailey Roemer, Maria Salvatierra, Mei Jiang, Luisa Maren Solis, Sevinj Isgandarova, Juan Carlos Amador Molina, Hsinyi Lu, Christian Valladolid Brown, Klaudia A. Szymonowicz, Ecaterina Elena Dumbrava, Natalie Ngoi, Ken Chen, Funda Meric-Bernstam, Cara L. Haymaker, Timothy A. Yap
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162487863
Cites:
Cited by:
Related to: